My watch list
my.bionity.com  
Login  

VEROVACCiNES GmbH

Inactivated subunit marker vaccines for the reduction of antibiotic use

VEROVACCiNES discovers and develops innovative vaccine solutions, to protect animals against infectious diseases. Key is a novel, broadly applicable, yeast-based technology to generate subunit marker vaccines. This technology has been validated by demonstrating protection of several target animal species against different viral diseases (proof-of-concept).

VEROVACCiNES GmbH is a spin-off company of the Martin Luther University Halle-Wittenberg, Germany in 2017. The company exclusively took over IP, brand, team, products and know-how from the former BMBF GO-Bio-funded VEROVACCiNES project at Halle University and continues phase 2 funding from the same BMBF GO-Bio program. We cooperate closely with international veterinary pharmaceutical companies, universities and research institutes, and we are eager to initiate new collaborations.

Founder

Hanjo Hennemann
CEO & Co-Founder

Sven-Erik Behrens
CSO & Co-Founder

Startup-Programme

Hugo-Junkers-Preis

Scidea

GO-Bio

More about VEROVACCiNES
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE